Tenet Healthcare Corporation (THC) — Fair Value Analysis

Base-case fair value (P50): $366.23 · Current price: $254.78 · Verdict: Undervalued

The Verdict on THC

Our Monte Carlo simulations indicate that TENET HEALTHCARE CORP (THC) is Undervalued at its current market price of $254.78. The P50 median fair value estimate derived from thousands of forward-looking scenarios stands at $366.23, implying a substantial +43.7% upside from the present level. This suggests that the market is not fully appreciating THC's underlying value, presenting a compelling opportunity for investors based on our quantitative models.

How THC stacks up against peers

While THC is Undervalued based on our fair value assessment, its quality tier is rated as "average" regarding operational and financial health against its sector. Despite the potential for a +43.7% gain to its P50 fair value of $366.23, this average quality rating suggests a balanced risk profile compared to peers. The gap between the $254.78 and the calculated $366.23 points to a favorable risk/reward, even with the company's average standing within its industry.

What this means for investors

Investors eyeing THC should note the significant projected upside from $254.78 to the $366.23 fair value, representing +43.7%. Our Monte Carlo analysis, which underpins the $366.23 estimate, models a wide range of future economic and company-specific outcomes to arrive at this Undervalued verdict. While there are always downside scenarios, the current spread indicates a strong potential for appreciation. To gain deeper insights into THC's full bear and bull case distribution and track its fair value as new fundamentals are released, sign up for a FairCurve account.